Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344708 | 1.00 | BACE1 (0.54) | BACE1MIFCAPN1AKR1C3AKR1C2 | |
| SCHEMBL344620 | 0.84 | AKR1C3 (0.52) | AKR1C3AKR1C2ALDH1A1KDM4EMAPT | |
| SCHEMBL10878231 | 0.84 | AKR1C3 (0.49) | MIFAKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL344621 | 0.84 | AKR1C3 (0.52) | AKR1C3AKR1C2ALDH1A1KDM4EMAPT | |
| SCHEMBL4683661 | 0.84 | BACE1 (0.74) | BACE1MIFCAPN1ALDH1A1KDM4E | |
| SCHEMBL4683657 | 0.84 | BACE1 (0.74) | BACE1MIFCAPN1ALDH1A1KDM4E | |
| SCHEMBL19812517 | 0.82 | PTGER4 (0.54) | BACE1AKR1C3ALDH1A1KDM4EPKM | |
| SCHEMBL19812518 | 0.82 | PTGER4 (0.54) | BACE1AKR1C3ALDH1A1KDM4EPKM | |
| SCHEMBL6703981 | 0.80 | CYP3A4 (0.44) | BACE1CAPN1ALDH1A1KDM4EMAPT | |
| SCHEMBL8042468 | 0.79 | MIF (0.53) | BACE1MIFCAPN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | AmDerma Pharmaceuticals, LLC (US) | 2019-10-08 | — | — | US | claimed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | claimed |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | ACTION MEDICINES, S.L. (ES) | 2018-02-08 | — | — | US | claimed |
| US-9597303-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | AmDerma Pharmaceuticals, LLC (US) | 2017-03-21 | — | — | US | claimed |
| US-9592216-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2017-03-14 | — | — | US | claimed |
| US-20160008303-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | AmDerma Pharmaceuticals, LLC | 2016-01-14 | — | — | US | claimed |
| US-8980869-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea | AmDerma Pharmaceuticals, LLC (US) | 2015-03-17 | — | — | US | claimed |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | ACTION MEDICINES, S.L. (ES) | 2014-07-24 | — | — | US | claimed |
| US-8530454-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis | AmDerma Pharmaceuticals, LLC (US) | 2013-09-10 | — | — | US | claimed |
| EP-2620145-A2 | 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ | Action Medicines, S.L. (ES) | 2013-07-31 | — | — | EP | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | CYP24A1, CYP8B1, CYP26B1 | BACE1 1382/4885MIF 1909/4885CAPN1 3965/4885 |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP24A1, CYP8B1, CYP26B1 | BACE1 1382/4885MIF 1909/4885CAPN1 3965/4885 |
| US-20160008303-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP8B1, CYP24A1, CYP26B1 | BACE1 1586/4885MIF 2400/4885CAPN1 4019/4885 |
| US-20140206654-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL DYSCRASIAS AND CANCER OF AN ORGAN | HMBS, HCLS1, CYP2S1 | BACE1 4380/4885MIF 2099/4885CAPN1 4279/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | BACE1 2241/4885MIF 3090/4885CAPN1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.